Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

Evelo Biosciences to Present at Biocentury Newsmakers Conference

Cambridge, Mass. - September 6, 2016

Cambridge, Mass., Sep. 6, 2016/PRNewswire/– Evelo Biosciences, the pioneering immuno-microbiome company, developing therapeutics for cancer, autoimmune and inflammatory diseases, today announced that Simba Gill, Ph.D., President and CEO, will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Friday, September 9, 2016 at 1:30p EDT in Presentation Room 402/403. The conference is being held at the Millennium Broadway Hotel & Conference Center in New York, NY.


About Evelo Biosciences

Founded in 2014, Evelo Biosciences has established the pioneering therapeutics discovery and development platform based on the human immuno-microbiome, the inter-connected metasystem comprising the human immune system and the human microbiome.  Evelo is developing onco-microbials for the treatment of cancer and immuno-microbials for the treatment of autoimmune and inflammatory diseases. The company is translating its insights into the immuno-microbiome into a range of product candidates, which are being advanced toward first human testing in 2017.

For more information, please visit

Media Contact

Stefan Riley